Discussions show strong interest and recognition of the article’s importance, with comments on the decline in Humira's sales and market shifts to biosimilars, using tone and language that reflect curiosity and concern, indicating that the publication is seen as impactful in shaping future pharmaceutical landscapes.
AgreementModerate agreement
Most discussions acknowledge the importance of biosimilars and agree with the article's insights on market shifts and the sales decline of Humira®. There are mentions of biosimilars contributing to market changes, indicating support.
InterestHigh interest
Posts demonstrate high interest, with many discussing detailed market implications, patient switching behaviors, and future U.S. market entries, showing curiosity and investment in understanding the topic.
EngagementModerate engagement
Several comments reference specific data points, such as the 35% patient switch rate or sales figures, and analyze implications, reflecting a moderate level of deep engagement.
ImpactModerate impact
Participants believe the publication highlights significant market trends that could influence pharmaceutical practices and policy, suggesting a moderate to high perceived impact.
Abstract in brief
Humira® (adalimumab) has been a leading biologic drug with nearly $20 billion in sales in 2018, but faced a decline in 2019 after biosimilars entered the European market.
By late 2019, about 35% of European patients had switched to these biosimilars, contributing to a decrease in Humira®'s annual sales to around $19 billion.
The review discusses the impact of biosimilars on the adalimumab market, comparing their formulations, delivery, activity, and properties, while preparing the public for similar changes as these biosimilars are expected to enter the U.S. market in 2023.
Biologics include vaccines, hormones, monoclonal antibodies, and gene therapies produced by biological systems. They enable the creation of complex molecules that are difficult to synthesize chemically, revolutionizing…
This video explains biologics, including vaccines, hormones, and monoclonal antibodies, produced by biological systems. It highlights how biotechnology enables the creation of complex molecules that traditional…
1 s2.0 S2589871X22000857 Main | PDF | Dementia | Methodology
News
... 10.1016/j. [84] B. Florescu, C. Filip, D. Rosca, F. Damsa, Peculiarities of ... 2021.02.003. 71, https://doi.org/10.1007/s12520-021-01320-5. [417] L ...
Powder Technology, 384, 36–50. https://doi.org/10.1016/j.powtec.2021.02.003 ... terms of bubble size and foam stability across different pHs and dosages, ...
Fundamentals of Field Crop Breeding Springer 2022 | PDF | Plant ...
News
The PHS in wheat is characterised by premature germination of kernels in ... https://doi.org/10.1016/j.cj.2021.02.003. Liao S, Qin X, Luo L et al (2019) ...
Surgry Update 2021 MAMC | PDF | Science & Mathematics
News
10.1016/j.eururo.2017.11.001. Epub 2017 Nov 22. PMID: 29174580. 6. Nicolau C ... 2021.02.003. • El Boghdady M, Ewalds-Kvist BM. Laparoscopic Surgery ...